Researcher examining cell cultures under a microscope in a bright research lab, basic research drug discovery | Healthcare Discovery
|

The Discovery Gap: Why Tomorrow’s Medicines Start as Experiments Few Would Fund Today

The weight-loss drug in millions of refrigerators began with a question about a desert lizard. The test that diagnosed COVID began in a Yellowstone hot spring. The medicines of 2040 depend on questions just as strange, and fewer people are being paid to ask them.

Presented By Our Partners

The short answer: The discovery gap is the distance between curiosity-driven research and a drug asset someone will pay for. Investors and drugmakers increasingly fund medicines that already have human data, while the open-ended science that produces new targets and tools is harder to finance. History shows why that matters: GLP-1 drugs, PCR testing, CRISPR gene editing and sildenafil all trace back to work whose value nobody could predict at the time.

What Is the Discovery Gap?

Healthcare Discovery uses the term discovery gap for a funding pattern that has become hard to ignore. Money for drugs that have already reached human trials is plentiful. Global drugmakers spent record sums licensing molecules already in human testing in 2025 and 2026, many of them developed in China. Money for the stage before that, when a scientist is still asking what a protein does or why an organism survives where it should not, is scarcer. In the first half of 2026, the number of seed and Series A biotech financings fell to its lowest first-half level in a decade, even as total venture funding rose, according to BioCentury.

That early stage matters more than it looks. A 2018 analysis in the Proceedings of the National Academy of Sciences examined the published research behind all 210 new drugs the FDA approved from 2010 to 2016. Research funded by the National Institutes of Health contributed to every one of them, and more than 90 percent of that funding was aimed at the biology of the drugs’ targets rather than the drugs themselves (Cleary et al., 2018). Today’s medicines rest on yesterday’s basic science. Four stories show how.

A Desert Lizard and the GLP-1 Era

The Gila monster, a venomous lizard of the American Southwest, eats only a handful of large meals a year. Researchers at the NIH had shown in the 1980s that its venom acted on the pancreas, and that caught the attention of John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx. In 1992 Eng and colleagues described a new 39-amino-acid peptide from the venom, which they named exendin-4, in the Journal of Biological Chemistry (Eng et al., 1992). It turned out to act like GLP-1, a human gut hormone that prompts insulin release after a meal, with one crucial difference: it lasted far longer in the body.

The VA declined to patent the discovery because it did not address a veteran-specific condition, so Eng filed the patent himself. He then spent about three years trying to interest drug companies before Amylin Pharmaceuticals, a small San Diego biotech, licensed it after seeing his work at a 1996 American Diabetes Association meeting. Synthetic exendin-4 became exenatide, and in April 2005 the FDA approved it as Byetta, the first GLP-1 receptor agonist. Thirteen years separated the lizard from the pharmacy. The drug class it opened now includes semaglutide and tirzepatide, which have changed how medicine treats type 2 diabetes and obesity.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

A Hot Spring and the Test Everyone Took

In 1966, microbiologist Thomas Brock, then at Indiana University, was studying microbial life in Yellowstone’s thermal springs with a grant from the National Science Foundation. He and an undergraduate, Hudson Freeze, isolated a bacterium from Mushroom Spring that thrived at temperatures once thought to rule out life. Brock named it Thermus aquaticus and described it in the Journal of Bacteriology in 1969 (Brock and Freeze, 1969). The pair deposited a sample in the American Type Culture Collection, a public repository where any researcher could obtain it.

Nearly two decades later, scientists developing the polymerase chain reaction, or PCR, needed a DNA-copying enzyme that could survive repeated heating. They found it in that deposited culture. Taq polymerase made PCR practical and automatable, and it went on to power medical diagnostics, forensic DNA analysis and the COVID-19 tests that laboratories ran by the millions. Brock described everything he did as basic research. In 2013 he and Freeze received a Golden Goose Award, which honors federally funded research whose odd-sounding origins led to major public benefit.

Salt Ponds and the Gene Editing Revolution

In 1992, Francisco Mojica, a doctoral student at the University of Alicante in Spain, was studying how salt-loving microbes from the nearby Santa Pola salt marshes adapt to changes in salinity. Sequencing their DNA, he noticed short repeats spaced at regular intervals. He spent the following years working out what they were, proposed the name CRISPR, and in 2005 published evidence that the sequences between the repeats matched DNA from viruses and plasmids, pointing to a microbial immune system (Mojica et al., 2005). Several journals turned the paper down before it found a home.

Other scientists later turned that microbial defense into a programmable gene editing tool. On December 8, 2023, the FDA approved Casgevy for sickle cell disease, the first approved therapy built on CRISPR-Cas9 editing. A question about how microbes survive in brine ended in a one-time treatment for an inherited blood disease.

When a Failure Becomes the Finding

Discovery is not only about curiosity research. Sometimes it is about what a failing program reveals. In 1989, Pfizer chemists in Sandwich, England, selected a compound called UK-92,480 for development as a possible treatment for angina. By mid-1993 it looked unpromising for the heart, but volunteers in an early multiple-dose study had commonly reported an unexpected side effect: penile erections. Pfizer pursued it, and in March 1998 the FDA approved sildenafil as Viagra. In 2005 the same molecule was approved as Revatio for pulmonary arterial hypertension (Ghofrani et al., 2006).

The lesson is not that every failure hides a blockbuster. It is that organizations running their own experiments see things outsiders never do. A company that only buys finished assets inherits the result, not the surprises along the way.

Why the Gap Is Widening

All four stories share a shape: an open question, years of work with no product in sight, and a payoff nobody could have written into a business plan. That shape fits poorly with how capital now flows. Investors prefer companies whose next milestone can be priced, and drugmakers increasingly fill their pipelines by licensing molecules that have already been tested in people. Our sister publication Healthcare Venture Capital Fund examines the investor side of this shift in Who Will Fund Discovery?, and our own overview of healthcare venture capital in 2026 maps where that money is moving.

None of that makes those choices wrong. Licensing finished assets gets medicines to patients, and specialization across countries can lower costs. The risk is slower and subtler: if fewer people are paid to ask open-ended questions, fewer discoveries like exendin-4 or Thermus aquaticus get made, and the shortage shows up a decade or two later as a thinner pipeline. Artificial intelligence may change the cost of early research, a possibility we examined in The One-Person Biotech and in our look at generative biology.

What This Means for You

For patients and health-minded readers, the discovery gap is not an abstract policy debate. The treatments you may rely on in 2040 are being found, or not found, right now. Healthcare Discovery’s view of longevity rests on a simple bridge: stay healthy through the fundamentals long enough to benefit from the breakthroughs that are coming. That bridge only works if the breakthroughs keep coming.

  • Read health news with the pipeline in mind. A “new drug” headline is usually about development. A story about a newly discovered mechanism or target is about discovery, and is often the earlier signal.
  • Look at who funds research on conditions you care about. Disease foundations such as the Cystic Fibrosis Foundation have shown that patient communities can fund early science that industry passes over.
  • Consider taking part in research. Registries, biobanks and observational studies, many listed on ClinicalTrials.gov, feed the basic science that later becomes treatment.
  • Keep the fundamentals working for you. Nutrition, sleep, movement, breathwork and mindset are how you buy time for science to catch up.

The Bottom Line

Every medicine in this story began as a question with no business case. The discovery gap is the growing distance between questions like those and the money willing to answer them. Watching that gap, and the people working to close it, is part of what Healthcare Discovery exists to do.

References

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

No spam. Unsubscribe anytime. We respect your inbox.

Similar Posts